Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
May 17 2022 - 7:30AM
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry
A. Neil, M.D., President and Chief Executive Officer, will present
virtually at the H.C. Wainwright Global Life Sciences Conference
being held May 23-26, 2022. The pre-recorded formal presentation
will be made available on Tuesday, May 24, 2022 at 7:00 AM ET.
A webcast of the pre-recorded presentation can
be accessed under the “News/Events” page in the Investors section
of the Company’s website, www.avalotx.com.
About Avalo TherapeuticsAvalo
Therapeutics is a leading clinical-stage precision medicine company
that discovers, develops, and commercializes targeted therapeutics
for patients with significant unmet clinical need in immunology and
rare genetic diseases. The Company has built a diverse portfolio of
innovative therapies to deliver meaningful medical impact for
patients in urgent need. The Company’s clinical candidates commonly
have a proven mechanistic rationale, biomarkers and/or an
established proof-of-concept to expedite and increase the
probability of success.
For more information about Avalo, please visit
www.avalotx.com.
Forward-Looking StatementsThis
press release may include forward-looking statements made pursuant
to the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are statements that are not historical
facts. Such forward-looking statements are subject to significant
risks and uncertainties that are subject to change based on various
factors (many of which are beyond Avalo’s control), which could
cause actual results to differ from the forward-looking statements.
Such statements may include, without limitation, statements with
respect to Avalo’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “might,” “will,” “could,” “would,” “should,”
“continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,”
“anticipates,” “estimates,” “intends,” “plans,” “potential,” or
similar expressions (including their use in the negative), or by
discussions of future matters such as: the future financial and
operational outlook; the development of product candidates or
products; timing and success of trial results and regulatory
review; potential attributes and benefits of product candidates;
and other statements that are not historical. These statements are
based upon the current beliefs and expectations of Avalo’s
management but are subject to significant risks and uncertainties,
including: Avalo's cash position and the potential need for it to
raise additional capital; drug development costs, timing and other
risks, including reliance on investigators and enrollment of
patients in clinical trials, which might be slowed by the COVID-19
pandemic; reliance on key personnel, including as a result of
recent management changes; regulatory risks; general economic and
market risks and uncertainties, including those caused by the
COVID-19 pandemic and tensions in Ukraine; and those other risks
detailed in Avalo’s filings with the SEC. Actual results may differ
from those set forth in the forward-looking statements. Except as
required by applicable law, Avalo expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Avalo’s expectations with respect thereto or
any change in events, conditions or circumstances on which any
statement is based.
For investor inquiries
Christopher Sullivan, CFOAvalo Therapeutics,
Inc.csullivan@avalotx.com410-803-6793
or
Chris BrinzeyICR
WestwickeChris.brinzey@westwicke.com339-970-2843
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalo Therapeutics (NASDAQ:AVTX)
Historical Stock Chart
From Sep 2023 to Sep 2024